Evolus, Inc. (EOLS): Long-Term Debt
$146.10M
As of 2025-12-31
$156.74M
As of 2026-06-30
+26.7%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $146.10M | +20.2% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $121.51M | +1.0% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $120.36M | +67.4% | 2024-03-07, Balance as of period end |
| 2022-12-31 | $71.88M | +0.9% | 2023-03-08, Balance as of period end |
| 2021-12-31 | $71.22M | n/a | 2022-03-03, Balance as of period end |
| No annual figure between 2019-12-31 and 2021-12-31. | |||
| 2019-12-31 | $73.51M | n/a | 2020-02-25, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $99.00M | +106.3% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $494.86M | +31.7% |
Compare EOLS, XERS, HROW, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗